AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
Saturday, December 12, 2020
AstraZeneca to buy Alexion for $39 billion to expand in immunology
AstraZeneca to buy Alexion for $39 billion to expand in immunology
Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases.
0 comments:
Post a Comment